AUS
NZ
UK
CA
USA
IND
Highlights
- atai Life Sciences to raise approximately $55 million through a public offering of 26.19 million shares.
- Offering proceeds will support clinical development and general corporate purposes.
- Berenberg acts as the sole bookrunner for the offering, expected to close February 14, 2025.
atai Life Sciences (NASDAQ:ATAI) has announced the pricing of a registered underwritten public offering, in which the company will sell 26,190,477 common shares at a price of $2.10 per share. This offering is expected to raise approximately $55 million in gross proceeds, before accounting for underwriting discounts and other related expenses. The public offering is designed to provide atai Life Sciences with the necessary capital to continue advancing its clinical programs and meet other general corporate needs.
Offering Details and Underwriting
The offering includes a 30-day option for the underwriter, Berenberg, to purchase an additional 3,928,571 common shares at the same price. This option would allow the company to raise additional capital if fully exercised, further increasing the offering's total gross proceeds. Berenberg is serving as the sole bookrunner for the offering, ensuring that the process is efficiently managed. The offering is expected to close on February 14, 2025, subject to customary closing conditions.
Use of Proceeds
The proceeds from the offering will primarily be used for general corporate purposes, including enhancing working capital. A significant portion of the funds will be allocated to advancing the clinical development of atai Life Sciences' product candidates and ongoing programs. This capital injection is crucial for furthering the company's research and clinical trials, particularly in the psychedelic and mental health spaces, where atai has established itself as a leader in innovation.
Registration and Offering Structure
This offering is being made through an effective shelf registration statement that was filed with the SEC on July 1, 2022, and subsequently declared effective on July 11, 2022. This structure allows atai Life Sciences to tap into the capital markets more efficiently by providing investors with a transparent and regulated process. The offering is priced at $2.10 per share, which may represent a discount compared to the company's recent market price, potentially leading to shareholder dilution.
Potential Impact on Shareholders
While the offering will provide much-needed funds for the company’s growth and development, it also carries the potential for significant shareholder dilution. The issuance of 26.19 million new shares will increase the total share count, potentially reducing the value of existing holdings. Furthermore, the additional 3.93 million shares that may be issued if the underwriter exercises its option could lead to further dilution for current shareholders.
Despite the dilution concerns, the offering represents an essential step for atai Life Sciences as it works to expand its clinical programs and explore new opportunities in the mental health and psychedelic medicine sectors. The capital raised will allow the company to accelerate its research efforts and bring innovative treatments to market.
